sPLA2-IIA Biomarker Assay for Targeted COVID-19 Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for COVID-19 and post-acute sequelae of SARS-CoV-2 infection (PASC) lack targeted therapies, with inconsistent associations between clinical findings and symptom severity, necessitating the identification of underlying pathobiological mechanisms for effective therapeutic targets.

Innovation Solution

The use of secreted phospholipase A2 (sPLA2) isoforms, particularly sPLA2-IIA, and blood urea nitrogen (BUN) levels for diagnosing and treating COVID-19 and PASC, involving assays and administration of sPLA2 inhibitors to manage elevated levels, thereby providing a targeted therapeutic approach.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If current treatments for COVID-19 are used, then general symptom management is provided, but there is a lack of targeted therapy and inconsistent association with symptom severity

Engineering Contradiction:

Improvetargeted therapyVSAvoidtreatment effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies local quality by measuring specific biomarker levels (sPLA2-IIA and BUN) in individual patients to determine treatment eligibility. Instead of uniform treatment, the therapy is tailored to patients with elevated sPLA2-IIA levels, creating localized precision in treatment application based on individual biochemical characteristics

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent utilizes parameter changes by monitoring sPLA2-IIA and BUN levels as quantitative parameters to identify patients who would benefit from sPLA2 inhibition therapy. The treatment decision is based on specific threshold values of these parameters, enabling objective classification and targeted intervention

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If sPLA2 inhibitors are administered to patients with elevated sPLA2-IIA levels, then targeted treatment is provided, but requires complex biomarker assessment

Engineering Contradiction:

Improvepersonalized treatmentVSAvoiddiagnostic complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent applies universality by using a single biomarker panel (sPLA2-IIA and BUN) that serves multiple functions: disease severity assessment, treatment eligibility determination, and monitoring of therapeutic response. This multi-functional biomarker approach simplifies the diagnostic process while enabling comprehensive patient management

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent introduces sPLA2-IIA and BUN levels as intermediary biomarkers that mediate between clinical presentation and treatment decision. These biomarkers serve as objective intermediaries that translate complex clinical scenarios into actionable treatment decisions, reducing diagnostic complexity

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20240052352A1Compositions and methods for characterizing and treating diseases and disorders associated with multiple organ failure

Publication Date: 2024.02.15 THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

AI summary

Provided herein are biomarkers for screening and monitoring of conditions, diseases, and disorders. In particular, provided herein are sPLA2 biomarkers for use in characterizing, prognosing, and treating disorders associated with elevated sPLA2.